CINXE.COM

<!DOCTYPE html> <html xmlns="http://www.w3.org/1999/xhtml"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=UA-5483862-1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-5483862-1'); </script>  <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-NFW5DS9');</script>  <script> //------------------------------------------------------- var z_account = "2632C1D8-6432-4D3A-93D6-08AAECC53F86"; var z_collector = "asgct.informz.net"; var z_cookieDomain = ".asgct.org"; //------------------------------------------------------- (function (e, o, n, r, t, a, s) { e[t] || (e.GlobalSnowplowNamespace = e.GlobalSnowplowNamespace || [], e.GlobalSnowplowNamespace.push(t), e[t] = function () { (e[t].q = e[t].q || []).push(arguments) }, e[t].q = e[t].q || [], a = o.createElement(n), s = o.getElementsByTagName(n)[0], a.async = 1, a.src = r, s.parentNode.insertBefore(a, s)) }(window, document, "script", "https://"+z_collector+"/web_trk/sp.js", "informz_trk")), informz_trk("newTracker", "infz", z_collector + "/web_trk/collector/", { appId: z_account, cookieDomain: z_cookieDomain }), informz_trk("setUserIdFromLocation", "_zs"), informz_trk("enableActivityTracking", 30, 15); informz_trk("trackPageView", null); </script> <meta charset="utf-8"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta name="viewport" content="width=device-width,user-scalable=no,maximum-scale=1.0,initial-scale=1.0"> <link href="/BlueKey/assets/css/app.css" rel="stylesheet"> <meta name="twitter:card" content="summary_large_image" /> <meta name="twitter:description" content="" /> <meta name="twitter:title" content="" /> <meta name="twitter:site" content="https://twitter.com/ASGCTherapy" /> <meta name="twitter:image" content="https://www.asgct.org/getattachment/f3d0cece-ee8a-4819-812a-98b4d65398b9/attachment.aspx" /> <meta name="twitter:creator" content="@ASGCTherapy" /> <script type="text/javascript" src="//platform-api.sharethis.com/js/sharethis.js#property=5ae883c34d3f70001197fe0b&product=inline-share-buttons"></script>  <script> (function (h, o, t, j, a, r) { h.hj = h.hj || function () { (h.hj.q = h.hj.q || []).push(arguments) }; h._hjSettings = { hjid: 1655159, hjsv: 6 }; a = o.getElementsByTagName('head')[0]; r = o.createElement('script'); r.async = 1; r.src = t + h._hjSettings.hjid + j + h._hjSettings.hjsv; a.appendChild(r); })(window, document, 'https://static.hotjar.com/c/hotjar-', '.js?sv='); </script> <script type="text/javascript"> adroll_adv_id = "LMOGHWAXC5CQHBCHNDJOMB"; adroll_pix_id = "PLJOCPLDXJHPLKUBZAWMIO"; adroll_version = "2.0"; (function(w, d, e, o, a) { w.__adroll_loaded = true; w.adroll = w.adroll || []; w.adroll.f = [ 'setProperties', 'identify', 'track' ]; var roundtripUrl = "https://s.adroll.com/j/" + adroll_adv_id + "/roundtrip.js"; for (a = 0; a < w.adroll.f.length; a++) { w.adroll[w.adroll.f[a]] = w.adroll[w.adroll.f[a]] || (function(n) { return function() { w.adroll.push([ n, arguments ]) } })(w.adroll.f[a]) } e = d.createElement('script'); o = d.getElementsByTagName('script')[0]; e.async = 1; e.src = roundtripUrl; o.parentNode.insertBefore(e, o); })(window, document); adroll.track("pageView"); </script> <script type="text/javascript" defer="defer" src="https://extend.vimeocdn.com/ga/127349852.js"></script><meta charset="UTF-8" /> <link href="/App_Themes/Default/Images/favicon.ico" type="image/x-icon" rel="shortcut icon"/> <link href="/App_Themes/Default/Images/favicon.ico" type="image/x-icon" rel="icon"/> <title> December 2024 | ASGCT - American Society of Gene & Cell Therapy </title></head> <body class="LTR Safari Chrome Safari133 Chrome133 ENUS ContentBody ASGCTDefaultPage"  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NFW5DS9" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  <form method="post" action="/publications/the-patient-press/december-2024" id="aspnetForm"> <div class="aspNetHidden"> <input type="hidden" name="__CMSCsrfToken" id="__CMSCsrfToken" value="95r6eVJ473viAV5CEy4PjPxyEU1hjt9whMpuvN7BpxxNe/OXK8xo7MnJXii/D+EksKI7gGcZSrIkoNEbW2jSObijU7o=" /> <input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="" /> <input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" /> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="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" /> </div> <script type="text/javascript"> //<![CDATA[ var theForm = document.forms['aspnetForm']; if (!theForm) { theForm = document.aspnetForm; } function __doPostBack(eventTarget, eventArgument) { if (!theForm.onsubmit || (theForm.onsubmit() != false)) { theForm.__EVENTTARGET.value = eventTarget; theForm.__EVENTARGUMENT.value = eventArgument; theForm.submit(); } } //]]> </script> <script src="/WebResource.axd?d=UZQNzmZXG1IdUaHxtavOjRvGEvOmz1kvw97PqEaxzBy7Ys-tUotw-RqgdbsvC3g_7cXjehqAdA_N6kbuK73WBAVGdxo1&t=638628028040000000" type="text/javascript"></script> <input type="hidden" name="lng" id="lng" value="en-US" /> <script type="text/javascript"> //<![CDATA[ function PM_Postback(param) { if (window.top.HideScreenLockWarningAndSync) { window.top.HideScreenLockWarningAndSync(1080); } if(window.CMSContentManager) { CMSContentManager.allowSubmit = true; }; __doPostBack('ctl00$CMSPortalManager1$am',param); } function PM_Callback(param, callback, ctx) { if (window.top.HideScreenLockWarningAndSync) { window.top.HideScreenLockWarningAndSync(1080); }if (window.CMSContentManager) { CMSContentManager.storeContentChangedStatus(); };WebForm_DoCallback('ctl00$CMSPortalManager1$am',param,callback,ctx,null,true); } //]]> </script> <script src="/ScriptResource.axd?d=WTJtoz6EJe-loUBJ9stbRxqzgpVp8oo0KdZGkhGfcu6Lr7kb5LeNfx21FKi8mxEL1oDZOLAxiAqERpClgBx-A6lZ0DJ1qKcDZB1NuIbRd8o9S7aG0&t=7c776dc1" type="text/javascript"></script> <script src="/ScriptResource.axd?d=y6KGkkRaceYF_mkApXCXMQ_rMQVX59BlJ-ut-lQDHw88bR5bbS86epdVNwimj01duE6_OophLX4sBTOgb8_5dNLaY2Mx5DHMJj7Rbr4kPMV1-AOS5VF5-QEC8oG-_-aHoWoyqA2&t=7c776dc1" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ var CMS = CMS || {}; CMS.Application = { "isDialog": false, "isDebuggingEnabled": false, "applicationUrl": "/", "isRTL": "false", "imagesUrl": "/CMSPages/GetResource.ashx?image=%5bImages.zip%5d%2f" }; //]]> </script> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="23D5A2CF" /> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAAIte8XIaNs08+P486pg+TOlWc/UGC0MiqcU6HCwvNVJvtiCdvXAe9fHd5B+sfVXgiDgRS76" /> </div> <script type="text/javascript"> //<![CDATA[ Sys.WebForms.PageRequestManager._initialize('ctl00$manScript', 'aspnetForm', ['tctl00$ctxM',''], [], [], 90, 'ctl00'); //]]> </script> <div id="ctl00_ctxM"> </div> <div class="wide"> <header> <div class="container"> <div class="logo"><a href="/"><img src="/BlueKey/assets/images/logo.png" alt="American Society of Gene and Cell Therapy"></a></div> <div class="topSearchWrapper"> <div class="topSearch"> <input type="text" placeholder="Enter Search Text Here"> <input type="submit" value="Go"> </div> <div class="topSearchToggle"></div> </div> <div class="topLinks"> <ul> <li><a href="/contact">Contact Us</a></li> </ul> </div> <div class="socialLinks topSocial"> <ul> <li><a href="https://twitter.com/ASGCTherapy" target="_blank"><i class="bk-icon-twitter"></i></a></li> <li><a href="https://www.facebook.com/asgctherapy" target="_blank"><i class="bk-icon-facebook"></i></a></li> <li><a href="https://www.instagram.com/asgctherapy" target="_blank"><i class="bk-icon-instagram"></i></a></li> <li><a href="https://www.youtube.com/user/ASGCT" target="_blank"><i class="bk-icon-youtube"></i></a></li> <li><a href="https://www.linkedin.com/company/asgct/" target="_blank"><i class="bk-icon-linkedin"></i></a></li> </ul> </div> <div class="topActions"> <input type="submit" name="ctl00$bkSiteHeader$logoutButton$btnSignOut" value="Member Login" id="ctl00_bkSiteHeader_logoutButton_btnSignOut" class="signoutButton btn btn-accent3 ghost btn-default" /> </div> <div class="menuToggle"></div> </div> <div id="ctl00_bkSiteHeader_headerBanner"> <div class="header-alert"> <div class="container"> <p><b><a href="https://annualmeeting.asgct.org/register">Feb. 20: Last day to receive early registration rates for #ASGCT2025! Lock in your spot to join us in New Orleans!</a></b></p> </div> </div> </div> <div class="navShade"></div> <div class="mainNav"> <div class="container"> <ul id="cmsMainNav" class="CMSListMenuUL"> <li class="CMSListMenuLIhasChildren"> <a class="CMSListMenuLink" href="/annual-meeting">Annual Meeting</a> <div class="menu-wrap"> <ul id="column1" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/annual-meeting/registration">Register</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/annual-meeting/sponsor-exhibit">Sponsor & Exhibit</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/annual-meeting/future-annual-meetings">Future Annual Meetings</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/annual-meeting/annual-meeting-archives">Annual Meeting Archives</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/annual-meeting/annual-meeting-archives/27th-annual-meeting-video-archive">27th Annual Meeting Video Archive</a></li></ul></li></ul> <ul id="column2" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/annual-meeting/program">Program</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/annual-meeting/program/workshops">Workshops</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/annual-meeting/program/keynote-speakers">Keynote Speakers</a></li></ul></li></ul> <ul id="column3" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/annual-meeting/abstracts">Abstracts</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/annual-meeting/abstracts/present">Present</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/annual-meeting/abstracts/awards">Awards</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/annual-meeting/abstracts/topics">Topics</a></li></ul></li></ul> </div> </li> <li class="CMSListMenuLIhasChildren"> <a class="CMSListMenuLink" href="/membership">Membership</a> <div class="menu-wrap"> <ul id="column1" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/membership/video-library">Video Library</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/membership/video-library/annual-meeting">Annual Meeting</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/membership/video-library/cancer">Cancer</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/membership/video-library/career-skills">Career Skills</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/membership/video-library/gene-editing">Gene Editing</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/membership/video-library/patients-and-clinicians">Patients and Clinicians</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/membership/video-library/regulatory">Regulatory</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/membership/video-library/aav">Viral Vectors</a></li></ul></li></ul> <ul id="column2" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/membership/become-a-member">Become a Member</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/membership/get-involved">Get Involved</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href=" http://jobs.asgct.org/" target="_blank">Career Center</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/membership/submit-an-abstract">ASGCT Abstracts</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/membership/submit-an-abstract/asgct-abstract-submission-windows">Abstract Submission Windows</a></li></ul></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/membership/volunteer">Volunteer</a></li></ul> <ul id="column3" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/membership/my-profile">My Profile</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/membership/economy-based-rates">Economy-Based Rates</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/membership/grants-awards">Awards</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/membership/membership-directory-new">Membership Directory</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/membership/scientific-committees">Scientific Committees</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/membership/standing-committees">Standing Committees</a></li></ul> </div> </li> <li class="CMSListMenuLIhasChildren"> <a class="CMSListMenuLink" href="/events">Events</a> <div class="menu-wrap"> <ul id="column1" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/events/around-the-world-advanced-therapy-medicinal-produc">Around the World: Advanced Therapy Medicinal Production in South America</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/events/career-development-seminars">Professional Development Cafés</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/events/career-development-seminars/intellectual-property-and-what-you-need-to-know">Intellectual Property and What You Need to Know</a></li></ul></li></ul> <ul id="column2" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/events/class-considerations-on-immunogenicity-for-aav-gen">Class Considerations on Immunogenicity for AAV GT Products: Assessing Current Practice + New Data</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/events/empowering-patients-2025-a-cell-and-gene-therapies">Empowering Patients 2025: A Cell and Gene Therapies Summit</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/events/the-big-picture-accountability-in-an-evolving-ecos">The Big Picture: Accountability in an Evolving Ecosystem</a></li></ul> <ul id="column3" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/events/molecular-therapy-presents-extracellular-vesicles">Molecular Therapy Presents: Extracellular Vesicles</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/events/non-asgct-events">Non-ASGCT Events</a></li></ul> </div> </li> <li class="CMSListMenuLIhasChildren"> <a class="CMSListMenuLink" href="/awards">Awards</a> <div class="menu-wrap"> <ul id="column1" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/awards/honorific-awards">Honorific Awards</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/awards/honorific-awards/outstanding-achievement-award">Outstanding Achievement Award</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/awards/honorific-awards/outstanding-new-investigator-awards">Outstanding New Investigator Awards</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/awards/honorific-awards/george-stamatoyannopoulos-mentorship-award">George Stamatoyannopoulos Mentorship Award</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/awards/honorific-awards/excellence-advancing-diversity-equity-inclusion">Award for Excellence in Advancing Diversity, Equity, and Inclusion</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/awards/honorific-awards/exemplary-service-award">Exemplary Service Award</a></li></ul></li></ul> <ul id="column2" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/awards/annual-meeting-awards">Annual Meeting Awards</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/awards/underrepresented-populations-fellowship">Underrepresented Populations in Gene and Cell Therapy</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/awards/mavis-agbandje-mckenna-scholarship-and-fund">Mavis Agbandje-McKenna Scholarship and Fund</a></li></ul> <ul id="column3" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/awards/career-development-awards">Career Development Awards</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/awards/congressional-policy-fellowship">Congressional Policy Fellowship</a></li></ul> </div> </li> <li class="CMSListMenuLIhasChildren"> <a class="CMSListMenuLink" href="/education">Outreach</a> <div class="menu-wrap"> <ul id="column1" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/education/clinicaltrials">Clinical Trials Finder</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/education/lunch-learn-events">Community Quick Takes</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/education/lunch-learn-events/informed-consent">Informed Consent</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/education/lunch-learn-events/state-of-the-field-highlights-approvals-for-cgt">State of the Field Highlights + Approvals for CGT in 2023</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/education/lunch-learn-events/access-to-approved-cell-and-gene-therapies">Access to Approved Cell and Gene Therapies</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/education/lunch-learn-events/genetic-testing-and-clinical-trial-eligibility">Genetic Testing and Clinical Trial Eligibility</a></li></ul></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/education/diversity-equity-and-inclusion-mission-goals">Diversity, Equity, and Inclusion</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/education/diversity-equity-and-inclusion-mission-goals/biotech-discovery-labs-program">Biotech Discovery Labs Program</a></li></ul></li></ul> <ul id="column2" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/education/gene-therapy-101">Patient Education: Gene Therapy 101</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/education/gene-therapy-101/gene-therapy-basics">Gene Therapy Basics</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/education/gene-therapy-101/gene-therapy-approaches">Gene Therapy Approaches</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/education/gene-therapy-101/developing-a-treatment">Clinical Trials Process</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/education/gene-therapy-101/vectors-101">Vectors 101</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/education/gene-therapy-101/gene-editing">Gene Editing</a></li></ul></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/education/global-outreach">Global Outreach</a></li></ul> <ul id="column3" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/education/disease-treatments">Patient Education: Condition Treatments</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/education/disease-treatments/beta-thalassemia-other-blood-disorders">Beta Thalassemia & Other Blood Disorders</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/education/disease-treatments/leukodystrophy">CALD and MLD</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/education/disease-treatments/spinal-muscular-atrophy">Spinal Muscular Atrophy</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/education/disease-treatments/blood-cancers-car-t-cell-therapy">CAR-T Basics</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/education/disease-treatments/hemophilia-gene-therapy">Hemophilia</a></li></ul></li></ul> </div> </li> <li class="CMSListMenuLIhasChildren"> <a class="CMSListMenuLink" href="/publications">Publications</a> <div class="menu-wrap"> <ul id="column1" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/publications/news">ASGCT Blog</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/publications/the-patient-press">The Patient Press</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/publications/the-patient-press/december-2024">December 2024</a></li></ul></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/publications/the-vector">The Vector</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/publications/landscape-report">Quarterly Gene, Cell, and RNA Therapy Landscape Report</a></li></ul> <ul id="column2" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/publications/asgct-podcast-network">ASGCT Podcast Network</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/publications/asgct-podcast-network/giants-of-gene-therapy">Giants of Gene Therapy</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/publications/asgct-podcast-network/the-issue">The Issue</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/publications/asgct-podcast-network/the-molecular-therapy-podcast">The Molecular Therapy Podcast</a></li></ul></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/publications/the-advocate">The Advocate</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/publications/the-advocate/subscribe-to-the-advocate">Subscribe to The Advocate</a></li></ul></li></ul> <ul id="column3" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/publications/molecular-therapy">Molecular Therapy Family</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/publications/molecular-therapy/molecular-therapy-presents-targets-and-biomarkers">Molecular Therapy Presents Extracellular Vesicles</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/publications/molecular-therapy/cell-press-webinar-advances-in-viral-vector-gene-d">Cell Press Webinar: Advances in Viral Vector Gene Delivery for CT Biomanufacturing</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/publications/molecular-therapy/molecular-therapy">Molecular Therapy</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/publications/molecular-therapy/mt–methods-clinical-development">MT Methods & Clinical Development</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/publications/molecular-therapy/mt–nucleic-acids">MT Nucleic Acids</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/publications/molecular-therapy/mt–oncolytics">MT Oncology</a></li></ul></li></ul> </div> </li> <li class="CMSListMenuLIhasChildren"> <a class="CMSListMenuLink" href="/advocacy">Advocacy</a> <div class="menu-wrap"> <ul id="column1" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/advocacy/events-and-opportunities">Events and Opportunities</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/advocacy/events-and-opportunities/policy-summit">Policy Summit</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/advocacy/events-and-opportunities/asgct-fda-liaison-meeting-(1)">ASGCT-FDA Liaison Meeting</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/advocacy/events-and-opportunities/cgt-science-series">Cell + Gene Therapy Science Series</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/advocacy/events-and-opportunities/congressional-policy-fellowship">Congressional Policy Fellowship</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/advocacy/events-and-opportunities/fda-immune-responses-aav-vectors">FDA & ASGCT: Immune Responses to AAV Vectors</a></li></ul></li></ul> <ul id="column2" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/advocacy/policy-priorities">Policy Priorities</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/advocacy/policy-priorities/patient-access-overview">Patient Access Overview</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/advocacy/policy-priorities/regulatory-policy">Regulatory Policy</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/advocacy/policy-priorities/research-funding">Research Funding</a></li></ul></li></ul> <ul id="column3" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/advocacy/the-advocate">The Advocate</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/advocacy/the-advocate/subscribe-to-the-advocate">Subscribe to The Advocate</a></li></ul></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/advocacy/policy-statements-letters">Policy Statements & Letters</a></li></ul> </div> </li> <li class="CMSListMenuLIhasChildren"> <a class="CMSListMenuLink" href="/about">About</a> <div class="menu-wrap"> <ul id="column1" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/about/leadership">Leadership</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/about/leadership/board-officers">Board of Directors</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/about/leadership/scientific-committees">Scientific Committees</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/about/leadership/standing-committees">Standing Committees</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/about/leadership/staff">Staff</a></li></ul></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/about/careers">Work at ASGCT</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/about/careers/abstracts-manager">Abstracts Manager</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/about/careers/administrative-coordinator">Administrative Coordinator</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/about/careers/senior-marketing-manager">Senior Marketing Manager</a></li></ul></li></ul> <ul id="column2" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/about/media">Media</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/about/culture">Our Culture</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/about/strategic-plan">Strategic Plan</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/about/meeting-code-of-conduct">Meeting Code of Conduct</a></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/about/terms-and-conditions">Terms and Conditions</a></li></ul> <ul id="column3" style="display: block;"><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/about/mission-vision">Mission & Vision</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/about/mission-vision/bylaws">Bylaws</a></li></ul></li><li class="CMSListMenuLI"><a class="CMSListMenuLink is-link-large" href="/about/support">Support ASGCT</a><ul class="CMSListMenuUL-GRANDCHILD" style="display: block;"><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/about/support/annual-meeting-support">Annual Meeting Support</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/about/support/advertise-asgct-publications">Advertise in ASGCT Publications</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/about/support/support-asgct-s-digital-programs">Digital Programs</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/about/support/giving">Giving</a></li><li class="CMSListMenuLI-GRANDCHILD"><a class="CMSListMenuA-GRANDCHILD" href="/about/support/year-round-support">Year-Round Support</a></li></ul></li></ul> </div> </li> </ul> </div> <div class="mainNavClose"></div> </div> </header> <div class="masthead" style="background: url('/getattachment/Publications/The-Patient-Press/December-2024/patient-physician-web.png.aspx') 50% 50% no-repeat; background-size: cover;"> <div class="container"></div> </div> <section class="mainBody"> <div class="container"> <main> <h1>December 2024</h1> <h2><p>Providing timely updates for the patient advocate community!  </p></h2> <hr /> <p><a class="btn btn-accent3" href="https://asgct.informz.net/asgct/pages/Patient_Press_Signup" target="_blank">Subscribe to The Patient Press</a></p> <h3>In This Issue:</h3> <ul role="list"> <li aria-setsize="-1" data-aria-level="1" data-aria-posinset="1" data-font="Symbol" data-leveltext="" data-list-defn-props="{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"multilevel"}" data-listid="2" role="listitem"> <p paraeid="{3759ee31-b3aa-45c9-97c2-3ff83a597d5a}{115}" paraid="175912977">NEW Resources on Gene Therapy for <a href="https://patienteducation.asgct.org/disease-treatments/genetic-hearing-loss" target="_blank">Genetic Hearing Loss</a> and <a href="https://patienteducation.asgct.org/disease-treatments/attr-amyloidosis" target="_blank">ATTR Amyloidosis</a> </p> </li> <li aria-setsize="-1" data-aria-level="1" data-aria-posinset="1" data-font="Symbol" data-leveltext="" data-list-defn-props="{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"multilevel"}" data-listid="1" role="listitem"> <p paraeid="{3759ee31-b3aa-45c9-97c2-3ff83a597d5a}{135}" paraid="1239436858">Register for the <a href="https://www.asgct.org/asgct-events/march-2025/empowering-patients-2025-a-cell-and-gene-therapie?utm_source=Informz&utm_medium=Email&utm_campaign=ASGCT" target="_blank">Empowering Patients Summit</a> March 12 & 13, 2025 </p> </li> <li>Explore how <a data-informz-do-not-track="false" data-informz-link="true" data-informz-link-name="" href="https://annualmeeting.asgct.org/register/patient-advocates" target="_blank">Patient Advocates can Attend ASGCT’s Annual Meeting,</a> May 13 – 17</li> </ul> <p><img alt="" src="/getmedia/a45b2935-ca14-4239-a3e4-880dc76923ea/The-Patient-Press-Newsletter-Header-Image.aspx?width=648&height=233" style="width: 648px; height: 233px;" /></p> <h2>Events</h2> <p><a href="https://www.asgct.org/asgct-events/march-2025/empowering-patients-2025-a-cell-and-gene-therapie?_ga=2.26276541.1035663532.1728917423-1335923092.1725890207&_gl=1*19d0jdw*_ga*MTMzNTkyMzA5Mi4xNzI1ODkwMjA3*_ga_Q37QKR6TCJ*MTcyODkzODc5OC4xNDcuMS4xNzI4OTQzOTcxLjAuMC4w" target="_blank"><img alt="" src="/getmedia/5dbf7658-aae0-4aea-a989-1cb2dd3ee9a4/Empowering-Patients-Email-House-Ad-V2.aspx?width=649&height=150" style="width: 649px; height: 150px;" /></a></p> <h3 paraeid="{4ec12d31-738b-4703-8215-4a3f90a50ab4}{2}" paraid="303586409">🧬 Empowering Patients 2025: A Cell and Gene Therapies Summit  </h3> <p paraeid="{4ec12d31-738b-4703-8215-4a3f90a50ab4}{2}" paraid="303586409"><a href="https://www.asgct.org/asgct-events/march-2025/empowering-patients-2025-a-cell-and-gene-therapie" rel="noreferrer noopener" target="_blank">Register for free</a> to join us virtually on March 12 and 13, and view the full agenda to see our full line-up of speakers! Attendees will hear from and leading clinicians and scientist in the field including Drs. Peter Marks, Paula Cannon, Terry Flotte, Amy Waldman, Ray Wang, and Heather Lau –just to name a few! Help us share this event with patients, caregivers, and advocates, whether they’re new to CGTs, or well into their journey!</p> <h3 paraeid="{64ebcb85-a08d-47a0-9383-67d8997fb69f}{51}" paraid="1085491256">⚜️ Join us in New Orleans for ASGCT’s Annual Meeting: May 13-17, 2025 </h3> <p paraeid="{64ebcb85-a08d-47a0-9383-67d8997fb69f}{75}" paraid="1700854358"><a href="https://annualmeeting.asgct.org/register/patient-advocates" target="_blank">Explore patient advocate opportunities</a> at ASGCT’s <a href="https://annualmeeting.asgct.org/" target="_blank">28th Annual Meeting</a>. The Society offers a a complimentary registration program for eligible attendees, discounted exhibitor fees for non-profit organizations, as well as patient-focused sessions and networking opportunities. ASGCT is committed to providing opportunities for patient communities to learn about the latest scientific discoveries, and foster connections to researchers, clinicians, and other advocates in the CGT space.  </p> <h3 paraeid="{64ebcb85-a08d-47a0-9383-67d8997fb69f}{131}" paraid="779763787">🙋 Apply to Be a Member of the ASGCT Patient Outreach Committee </h3> <p paraeid="{64ebcb85-a08d-47a0-9383-67d8997fb69f}{141}" paraid="249879415"><a href="https://www.asgct.org/membership/volunteer/volunteer-to-serve-on-a-committee" rel="noreferrer noopener" target="_blank">Apply today</a> to be part of the committee developing <a href="https://patienteducation.asgct.org/" rel="noreferrer noopener" target="_blank">patient outreach materials</a>. The Society seeks foundation leaders, scientists, and clinicians to serve as volunteer leaders who will help shape ASGCT’s programming for the patient community. We are accepting applications for all <a href="https://www.asgct.org/membership/standing-committees" rel="noreferrer noopener" target="_blank">standing </a>and <a href="https://www.asgct.org/membership/scientific-committees" rel="noreferrer noopener" target="_blank">scientific</a> committees through Jan. 17. Term lengths for individuals accepted during the upcoming cycle begin in June 2025 and end in May 2028.  </p> <h3 lang="EN-US" paraeid="{de3d9510-854b-4bb6-bcbd-bb90dbb72102}{113}" paraid="172499818" xml:lang="EN-US">ASGCT + FDA Workshop on AAV Gene Therapy Immunogenicity Solutions </h3> <p lang="EN-US" paraeid="{4168c5f9-a784-4124-9702-fba1a543eabf}{29}" paraid="1840480115" xml:lang="EN-US">🧬 <a href="https://www.asgct.org/asgct-events/january-2025/class-considerations-on-immunogenicity-for-aav-gen?utm_source=Informz&utm_medium=Email&utm_campaign=ASGCT" target="_blank">Register for the free virtual scientific workshop</a> on Jan. 22 and 23 (9 a.m. - 1 p.m. ET on both days) exploring Class Considerations on Immunogenicity for AAV Gene Therapy Products.  </p> <h2>Resource Hub</h2> <p><a href="https://patienteducation.asgct.org/disease-treatments/genetic-hearing-loss" target="_blank"><img alt="" src="/getmedia/64dd3335-deb2-44ef-a7f7-2a745fa72402/Genetic-Hearing-Loss.aspx?width=300&height=150" style="width: 300px; height: 150px;" /></a>     <a href="https://patienteducation.asgct.org/disease-treatments/attr-amyloidosis" target="_blank"><img alt="" src="/getmedia/5a3d89d8-a477-4f36-a9e9-08b0068fc183/ATTR-(2).aspx?width=300&height=150" style="width: 300px; height: 150px;" /></a></p> <h3 paraeid="{4ec12d31-738b-4703-8215-4a3f90a50ab4}{254}" paraid="2033699344">NEW Patient Education Units Explore Hearing Loss, ATTR</h3> <p>👂 <a href="https://patienteducation.asgct.org/disease-treatments/genetic-hearing-loss" target="_blank">Genetic Hearing Loss</a> (GHL)</p> <p paraeid="{ffed1a31-7379-460e-a437-876391ffefe7}{5}" paraid="245242689">Genetic changes can impact how one's <a href="https://patienteducation.asgct.org/disease-treatments/genetic-hearing-loss" target="_blank">hearing system develops</a>, but gene therapy is paving the way for innovative treatments. Learn more about the genetic factors contributing to hearing loss and the ongoing research on gene therapies aimed at improving outcomes for individuals interested in potential treatment options. </p> <p paraeid="{ffed1a31-7379-460e-a437-876391ffefe7}{5}" paraid="245242689">⚕️ <a href="https://patienteducation.asgct.org/disease-treatments/transthyretin-amyloidosis" target="_blank">Transthyretin Amyloidosis</a></p> <p paraeid="{ffed1a31-7379-460e-a437-876391ffefe7}{56}" paraid="591917373"><a href="https://patienteducation.asgct.org/disease-treatments/attr-amyloidosis" target="_blank">Transthyretin amyloidosis (ATTR)</a> is a condition that gradually worsens over time and affects how certain organs work, especially the heart and nerves. This new unit explores the causes of ATTR amyloidosis and how new gene therapies are being developed to potentially slow or stop disease progression. </p> <p paraeid="{ffed1a31-7379-460e-a437-876391ffefe7}{62}" paraid="503637768" style="text-align: center;"><strong>Help us share this free-to-use content with your networks!</strong></p> <p paraeid="{ffed1a31-7379-460e-a437-876391ffefe7}{62}" paraid="503637768">Thank you to Akouos and Regeneron for supporting our Genetic Hearing Loss content and Intellia Therapeutics for supporting the ATTR Amyloidosis module. All support is delivered through unrestricted educational grants, and ASGCT is solely responsible for the content of all Patient Education modules.</p> <h3 paraeid="{ffed1a31-7379-460e-a437-876391ffefe7}{76}" paraid="28389842">⏲️ Community Quick Take: 5-minute answers from experts on timely topics</h3> <p paraeid="{ffed1a31-7379-460e-a437-876391ffefe7}{88}" paraid="2070961570">In partnership with the <a href="https://www.fusfoundation.org/" rel="noreferrer noopener" target="_blank">Focused Ultrasound Foundation</a>, the <a href="https://patienteducation.asgct.org/quick-takes/focused-ultrasound-in-cell-and-gene-therapies" rel="noreferrer noopener" target="_blank">latest CQT</a> explores the use of high-frequency sound waves to target and treat tissues. Beyond its established clinical uses, focused ultrasound shows promise in gene therapy, particularly for delivering large therapeutic compounds across the blood-brain barrier, a crucial step for treating brain disorders like ALS and <a href="https://patienteducation.asgct.org/disease-treatments/parkinsons-disease" rel="noreferrer noopener" target="_blank">Parkinson's disease</a>.  </p> <h3 paraeid="{ffed1a31-7379-460e-a437-876391ffefe7}{118}" paraid="1688862843">🏛️ Patient Focused Policy Positions </h3> <p paraeid="{ffed1a31-7379-460e-a437-876391ffefe7}{124}" paraid="1957352027"><a href="https://patienteducation.asgct.org/patient-journey/patient-focused-policy-positions" rel="noreferrer noopener" target="_blank">Review summaries</a> of important ASGCT Policy Positions focused on improving and advocating for the public health of individuals with rare diseases or disorders. This 10-minute read will enhance your understanding of policies that may affect your community’s CGT journey. </p> <h3 paraeid="{ffed1a31-7379-460e-a437-876391ffefe7}{191}" paraid="1656001573">📰 Latest Research from Breakthroughs in Muscular Dystrophy Event</h3> <p paraeid="{ffed1a31-7379-460e-a437-876391ffefe7}{205}" paraid="867994299">ASGCT hosted a scientific conference this month on the latest CGT research on muscular dystrophies. <a href="https://www.asgct.org/events/breakthroughs-in-muscular-dystrophy/abstracts" rel="noreferrer noopener" target="_blank">View the 15 plain language summaries</a> from abstracts that were presented during this event.</p> <h3 paraeid="{ffed1a31-7379-460e-a437-876391ffefe7}{230}" paraid="1777661781">📅  World AIDS Day</h3> <p paraeid="{ffed1a31-7379-460e-a437-876391ffefe7}{236}" paraid="1959305376"><a href="https://www.who.int/campaigns/world-aids-day/2024" rel="noreferrer noopener" target="_blank">Dec. 1 marked World AIDS Day</a>, a time to honor the strength and resilience of those living with HIV/AIDS and to celebrate the groundbreaking efforts of scientists working on innovative treatments. One exciting avenue of research is using cell and gene therapies to tackle HIV. The virus is notoriously difficult to treat because it changes rapidly and hides within immune cells. </p> <p paraeid="{ffed1a31-7379-460e-a437-876391ffefe7}{236}" paraid="1959305376"><a href="https://www.youtube.com/watch?v=dMbcGcwqspI" rel="noreferrer noopener" target="_blank">Watch a recent Congressional briefing</a> featuring ASGCT President Dr. Paula Cannon and other researchers actively working on CGT approaches to treat HIV. The briefing's audience also heard from <a href="https://www.cityofhope.org/patient-who-achieved-hiv-remission-shares-his-story" rel="noreferrer noopener" target="_blank">Paul Edmonds</a>, one of the only people in the world to be in total HIV remission after he received a bone marrow transplant from a donor with a rare HIV-resistant genetic variant. </p> <h3 paraeid="{cb9e84e6-fed1-46d6-98d7-3b2c74084048}{48}" paraid="1131990539">📅 Wilson Disease Awareness Day </h3> <p paraeid="{cb9e84e6-fed1-46d6-98d7-3b2c74084048}{56}" paraid="2016711289"><a href="https://patienteducation.asgct.org/disease-treatments/wilson-disease" rel="noreferrer noopener" target="_blank">Check out our resources on Wilson Disease</a> and learn how gene therapy can deliver a new ATP7B gene into cells to help restore proper liver function and remove excess copper in the body. On Dec. 6, we recognized Wilson Disease Awareness Day to honor the dedicated community working to advance understanding and develop therapies for this rare condition. </p> <h3 paraeid="{cb9e84e6-fed1-46d6-98d7-3b2c74084048}{103}" paraid="1180643442">📣 CBER Ensures Patient Voice Remains Central to Gene Therapy Development  </h3> <p paraeid="{cb9e84e6-fed1-46d6-98d7-3b2c74084048}{111}" paraid="1463591994"><a href="https://www.asgct.org/publications/news/november-2024/cber-committed-to-ensuring-patient-voice-remains-c" rel="noreferrer noopener" target="_blank">Read a recap</a> of the FDA's Center for Biologics Evaluation and Research (CBER) listening meeting held Sept. 20. Patients and caregivers shared their experiences, concerns, and informational needs on the topic of Patient and Care Partner Perspectives on Safety Considerations for Approved Gene Therapy Treatments. <a href="https://fda.zoomgov.com/rec/play/eX3UBjT_qSOGFoOj-hhf3EKK3oiHBgTS3DBBOiEikVlQSPDcQpkasvDbC2cKQBZ8kvOxGYg1SPZdMEga.5aWhJTP8fxiw70Vs?canPlayFromShare=true&from=share_recording_detail&continueMode=true&componentName=rec-play&originRequestUrl=https%3A%2F%2Ffda.zoomgov.com%2Frec%2Fshare%2FT3cXrUmVoinN2y6nywDe_9iyRq6erDRAYUHHV8aRnhPGRj2IO1n-pk_Bpsa7FyD3.Z-mbMWYG_Yx7NA8R" rel="noreferrer noopener" target="_blank">A recording is now available</a> for the second part of this listening session, Patient and Care Perspectives on Early Enrollment into Gene and Cell Therapy Clinical Trials for Rare Diseases. Stay tuned for a recap in the February edition.  </p> <h3 paraeid="{cb9e84e6-fed1-46d6-98d7-3b2c74084048}{164}" paraid="1525954834">🔬 Patient Focused Drug Development Workshop</h3> <p paraeid="{cb9e84e6-fed1-46d6-98d7-3b2c74084048}{180}" paraid="1861728387"><a href="https://www.fda.gov/drugs/news-events-human-drugs/patient-focused-drug-development-workshop-discuss-methodologic-and-other-challenges-related-patient?source=email#event-information" rel="noreferrer noopener" target="_blank">FDA hosted a virtual public workshop</a> to discuss how patient experiences help with understanding the risks and benefits of treatments, what goes on labels, and other important topics. Experts shared ideas about the best ways to collect and use patient feedback, while addressing challenges and opportunities to the implementation of such changes. FDA has invited stakeholders to submit comments to the <a href="https://www.regulations.gov/document/FDA-2024-N-4815-0001" rel="noreferrer noopener" target="_blank">public docket</a> through Feb. 11, 2025.  An event recording will be available soon.  </p> <h3>⭐ National Organization for Rare Disease NEW Living Rare Study and Drug Development Series</h3> <p lang="EN-US" paraeid="{15cb8b3f-9fb2-4b90-be1f-bd6ce113b066}{36}" paraid="989802639" xml:lang="EN-US">The National Organizations for Rare Disorders (NORD) <a href="https://learn.rarediseases.org/rare-disease-drug-development-series/" target="_blank">released a new drug development educational series</a> for patients and advocates to better understand their role in the drug development process. In addition, they have started the first ever large-scale study in the U.S. examing how the experiences and challenges of people impacted by rare disease changes over time. Check out the <a href="https://livingrarestudy.org/" target="_blank">Living Rare Study</a> and consider joining! </p> <h2>Breakthrough Moments</h2> <p><a href="https://www.asgct.org/about/support/advertise-asgct-publications" target="_blank"><img alt="" src="/ASGCT/media/about/Patient-Press-(2).png" /></a></p> <h3 paraeid="{62f737e8-43fc-4f88-a9b0-08606bcae11c}{187}" paraid="2114379712">🔜 Upcoming FDA Decision Dates  </h3> <p paraeid="{62f737e8-43fc-4f88-a9b0-08606bcae11c}{207}" paraid="901079795"><a href="https://ir.ionis.com/news-releases/news-release-details/ionis-announces-olezarsen-fcs-new-drug-application-accepted" rel="noreferrer noopener" target="_blank">Ionis Pharmaceuticals' Olezarsen</a> is an investigational Ligand Conjugated Antisense (LICA) therapy for the treatment of patients with familial chylomicronemia syndrome (FCS). FDA granted Olezarsen Priority Review and is expected to make a decision on its approval by Dec. 19. </p> <h3 paraeid="{62f737e8-43fc-4f88-a9b0-08606bcae11c}{227}" paraid="746000427">📰 Rare in the News</h3> <p paraeid="{2921cf15-8750-43ad-b71b-024080d23b0d}{27}" paraid="1042607756"><strong>GAO report of FDA’s rare disease efforts</strong> – The US Government Accountability Office (GAO) <a href="https://www.gao.gov/products/gao-25-106774?utm_campaign=usgao_email&utm_content=topic_health&utm_medium=email&utm_source=govdelivery" rel="noreferrer noopener" target="_blank">conducted a report</a> of FDA’s activities related to rare disease drug development and approval processes. Some of their key findings related to the agency’s approach on collaborating and receiving input from patient groups to help build staff expertise in reviewing drug applications; how they use flexibility in evidence requirements due to challenges like small patient populations, and how the rare disease hub was created to improve coordination between the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). </p> <p paraeid="{2921cf15-8750-43ad-b71b-024080d23b0d}{112}" paraid="736291138"><strong>Alzheimer’s disease</strong> - <a href="https://ir.lexeotx.com/news-releases/news-release-details/lexeo-therapeutics-announces-positive-interim-data-lx1001-first" rel="noreferrer noopener" target="_blank">Positive results were reported</a> from the first-ever gene therapy to target the underlying genetic cause of APOE4-associated Alzheimer’s disease by reducing harmful brain proteins linked to the disease.  </p> <p paraeid="{2921cf15-8750-43ad-b71b-024080d23b0d}{168}" paraid="1712920883"><strong>AADC deficiency</strong> – <a href="https://www.cgtlive.com/view/fda-approves-ptc-therapeutics-gene-therapy-upstaza-aadc-deficiency" rel="noreferrer noopener" target="_blank">FDA approved PTC Therapeutics’ gene therapy Kebilidi</a> (marketed as Upstaza in the EU), an AAV based gene therapy for the treatment of children and adults with aromatic L-amino acid decarboxylase (AADC) deficiency.  </p> <p paraeid="{2921cf15-8750-43ad-b71b-024080d23b0d}{205}" paraid="27329212"><strong>Batten disease</strong>* – A gene therapy <a href="https://www.fiercebiotech.com/biotech/neurogene-stops-batten-gene-therapy-after-fda-denies-request-dealing-double-dose-bad-news" rel="noreferrer noopener" target="_blank">program for CLN5 Batten disease was halted </a>after the FDA rejected its application for Regenerative Medicine Advanced Therapy (RMAT) designation. The decision significantly impacts patients with this rare neurodegenerative condition, as NGN-101 was the only investigational gene therapy in clinical trials for this subtype.  </p> <p paraeid="{d2e23655-5edc-432b-97cd-94db40031fc9}{1}" paraid="1202416410"><strong>Duchenne muscular dystrophy</strong>* – <a href="https://www.statnews.com/2024/11/18/duchenne-muscular-dystrophy-regenxbio-positive-data/" rel="noreferrer noopener" target="_blank">STAT reported on promising early results from Regenxbio’s</a> experimental gene therapy for DMD. Key findings included improved muscle function in a small group of boys aged 4–12. The therapy delivers microdystrophin, a lab-engineered protein, designed to mimic and potentially outperform natural dystrophin in durability and effectiveness. </p> <p paraeid="{d2e23655-5edc-432b-97cd-94db40031fc9}{36}" paraid="1425107134"><strong>Fabry disease</strong>* – Sangamo Therapeutics announced they <a href="https://endpts.com/sangamo-to-seek-accelerated-approval-for-fabry-gene-therapy/" rel="noreferrer noopener" target="_blank">will seek accelerated approval</a> for their Fabry disease gene therapy; the company also said that FDA may not require a confirmatory trial. </p> <p lang="EN-US" paraeid="{dbe127e5-0be6-4596-aaf4-4f1f1423209e}{19}" paraid="930022321" xml:lang="EN-US"><strong>Huntington's disease (HD) </strong>* – <a href="https://www.uniqure.com/investors-media/press-releases?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-9sOAo39OS7ouOc1iYwE8i5kZoH0TXgEJ4THjsJcySMVv4S1kBluUr_Og0LjOzexDkT2ibCO_E-fAqaTFMrgfi6erDtoA&_hsmi=337861550&utm_content=337861550&utm_source=hs_email" rel="noreferrer noopener" target="_blank">FDA agreed Phase I/II trial data</a> may support a Biologics License Application (BLA) for Accelerated Approval, marking a key milestone for the HD community, paving the way for a potentially life-changing therapy for this devastating neurodegenerative disorder. </p> <p paraeid="{d2e23655-5edc-432b-97cd-94db40031fc9}{87}" paraid="385833118"><strong>AL leukemia</strong>* – <a href="https://medcitynews.com/2024/11/autolus-car-t-cell-therapy-obe-cel-aucatzyl-fda-approval-b-cell-all-blood-cancer-leukemia/" rel="noreferrer noopener" target="_blank">FDA approved Aucatzyl,</a> the second CAR T-treatment for adults with B-cell precursor acute lymphoblastic leukemia (ALL). It targets the same protein as a prior approved drug for ALL, but is engineered to offer better safety and efficacy. Additionally, <a href="https://www.fiercepharma.com/pharma/it-was-good-lesson-fda-reconsiders-car-t-boxed-warning-secondary-cancers-peter-marks-says?source=email" rel="noreferrer noopener" target="_blank">FDA announced</a> they are reconsidering the boxed warning on CAR T products on the risk of secondary cancers. </p> <p paraeid="{d2e23655-5edc-432b-97cd-94db40031fc9}{165}" paraid="1796351056"><strong>Methylmalonic acidemia (MMA)</strong> – Thanks to a <a href="https://ncats.nih.gov/news-events/news/new-path-for-a-gene-therapy-trial-at-NIH-for-a-rare-metabolic-disease" rel="noreferrer noopener" target="_blank">collaboration between NCATS and NHGRI</a>, a halted gene therapy project for methylmalonic acidemia (MMA), a rare and life-threatening genetic disorder, is back on track. NIH has stepped in to lead the clinical trial which is expected to launch next year, after financial challenges ended Selecta Biosciences’ involvement. </p> <p paraeid="{d2e23655-5edc-432b-97cd-94db40031fc9}{212}" paraid="1468765302"><strong>Rett syndrome</strong> - <a href="https://endpts.com/patient-dies-in-neurogenes-rett-syndrome-study/" rel="noreferrer noopener" target="_blank">One patient died in Neurogene's</a> trial of a Rhett syndrome treatment after experiencing a rare and life-threatening immune response that can occur with high doses of AAV gene therapy. No other serious adverse events have been reported in the trial. ASGCT will be releasing patient education focused around AAV immune responses throughout 2025. </p> <p paraeid="{d2e23655-5edc-432b-97cd-94db40031fc9}{245}" paraid="511806599"><strong>Sickle Cell Disease</strong>* – <a href="https://www.biopharmadive.com/news/beam-sickle-cell-base-editing-study-data-abstract/731931/?" rel="noreferrer noopener" target="_blank">Beam Therapeutics announced</a> that a patient died in their trial of a gene editing trial for sickle cell disease (SCD). Investigators determined that the death was likely due to the busulfan conditioning treatment received prior to the therapy to prepare the bone marrow for the reinfusion of edited cells. Early results from other patients in the trial were broadly positive, however, and Beam announced they are working on a solution to eliminate the need for busulfan conditioning. </p> <h3 paraeid="{0fd5b6fe-23dd-49d8-a801-990d87bc39e2}{113}" paraid="2100592272">*Learn more</h3> <p>Visit ASGCT's patient-friendly resources on gene therapy for these diseases:</p> <ul> <li> <p><a href="https://patienteducation.asgct.org/disease-treatments/batten" rel="noreferrer noopener" target="_blank">Batten Disease</a> </p> </li> <li aria-setsize="-1" data-aria-level="1" data-aria-posinset="2" data-font="Symbol" data-leveltext="" data-list-defn-props="{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"multilevel"}" data-listid="13" role="listitem"> <p paraeid="{ba943aac-11f8-41b6-b711-a406583e8a40}{88}" paraid="729226219"><a href="https://patienteducation.asgct.org/disease-treatments/car-t-basics" rel="noreferrer noopener" target="_blank">Blood Cancers and CAR T-Cell Therapy</a> (Leukemia) </p> </li> <li aria-setsize="-1" data-aria-level="1" data-aria-posinset="3" data-font="Symbol" data-leveltext="" data-list-defn-props="{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"multilevel"}" data-listid="13" role="listitem"> <p paraeid="{ba943aac-11f8-41b6-b711-a406583e8a40}{99}" paraid="1387759335"><a href="https://patienteducation.asgct.org/disease-treatments/fabry" rel="noreferrer noopener" target="_blank">Fabry Disease</a>  </p> </li> <li aria-setsize="-1" data-aria-level="1" data-aria-posinset="4" data-font="Symbol" data-leveltext="" data-list-defn-props="{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"multilevel"}" data-listid="13" role="listitem"> <p lang="EN-US" paraeid="{ad83754f-380e-438f-9360-db855c0a5f0e}{16}" paraid="435320821" xml:lang="EN-US"><a href="https://patienteducation.asgct.org/" rel="noreferrer noopener" target="_blank">Huntington's Disease</a> </p> </li> <li aria-setsize="-1" data-aria-level="1" data-aria-posinset="5" data-font="Symbol" data-leveltext="" data-list-defn-props="{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"multilevel"}" data-listid="13" role="listitem"> <p paraeid="{ba943aac-11f8-41b6-b711-a406583e8a40}{108}" paraid="2142542348"><a href="https://patienteducation.asgct.org/disease-treatments/muscular-dystrophy" rel="noreferrer noopener" target="_blank">Muscular Dystrophy (Duchenne)</a> </p> </li> <li aria-setsize="-1" data-aria-level="1" data-aria-posinset="6" data-font="Symbol" data-leveltext="" data-list-defn-props="{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"multilevel"}" data-listid="13" role="listitem"> <p paraeid="{ba943aac-11f8-41b6-b711-a406583e8a40}{119}" paraid="1239588440"><a href="https://patienteducation.asgct.org/disease-treatments/sickle-cell-disease" rel="noreferrer noopener" target="_blank">Sickle Cell Disease</a> <br />  </p> </li> </ul> <p paraeid="{ba943aac-11f8-41b6-b711-a406583e8a40}{119}" paraid="1239588440" style="text-align: center;">Stay up to date on the latest patient-focused resources, events, and more by <u><a data-informz-do-not-track="false" data-informz-link="true" data-informz-link-name="" href="https://asgct.informz.net/asgct/pages/Patient_Press_Signup" target="_blank">subscribing to this newsletter</a></u> and/or forwarding to someone who might be interested.</p> <p paraeid="{0fd5b6fe-23dd-49d8-a801-990d87bc39e2}{169}" paraid="767150825" style="text-align: center;"><a class="btn btn-accent3" href="https://asgct.informz.net/asgct/pages/Patient_Press_Signup" target="_blank">Subscribe to The Patient Press</a></p> </main> <aside> <div class="asideBox"> <h4>Related Pages</h4> <ul> <li><a href="/publications/the-patient-press/october-2024">October 2024</a> </li> <li class="active"><a href="/publications/the-patient-press/december-2024">December 2024</a> </li class="active"> </ul> </div> </aside> </div> </section> <div class="event-row"> <div class="year">2025</div> <div class="content"> <h2>28th ASGCT Annual Meeting</h2> <p>May 13-17, 2025 | New Orleans</p> </div> <div class="action"><a class="btn btn-white" href="https://annualmeeting.asgct.org/register" target="_blank">Register Today!</a></div> </div> <footer> <div class="container"> <div class="footerColContainer"> <div class="footerCol"> <p><img alt="logo-footer.png" class="footerLogo" src="/getmedia/c77b7df1-12a2-4998-9809-0a880c107341/ASGCT_Web_Horz_White.aspx" title="logo-footer.png" /></p> <p>20800 Swenson Dr.<br /> Suite 300<br /> Waukesha, WI 53186</p> </div> <div class="footerCol"> <ul> <li><a href="/about">About</a></li> <li><a href="/membership">Membership</a></li> <li><a href="https://annualmeeting.asgct.org" target="_blank">Annual Meeting</a></li> <li><a href="http://www.cell.com/molecular-therapy-family/home" target="_blank">Journal</a></li> </ul> </div> <div class="footerCol"> <ul> <li><a href="/education">Education</a></li> <li><a href="/advocacy">Advocacy</a></li> <li><a href="https://asgct.org/awards" target="_blank">Awards</a></li> <li><a href="https://asgct.org/about/privacy-policy" target="_blank">Privacy Policy</a></li> </ul> </div> <div class="footerCol"> <p class="altStyle">Connect with ASGCT</p> <p><strong>Phone:</strong> 414.278.1341<br /> <a href="mailto:info@asgct.org">info@asgct.org</a><div class="footerSocial"><div id="ctl00_bkSiteFooter_rptFooterBlocks_ctl04_widget1_ctl00_divSocialLinks" class="socialLinks footerSocial"> <ul> <li><a href="https://twitter.com/ASGCTherapy" target="_blank"><i class="bk-icon-twitter"></i></a></li> <li><a href="https://www.facebook.com/asgctherapy" target="_blank"><i class="bk-icon-facebook"></i></a></li> <li><a href="https://www.instagram.com/asgctherapy" target="_blank"><i class="bk-icon-instagram"></i></a></li> <li><a href="https://www.youtube.com/user/ASGCT" target="_blank"><i class="bk-icon-youtube"></i></a></li> <li><a href="https://www.linkedin.com/company/asgct/" target="_blank"><i class="bk-icon-linkedin"></i></a></li> </ul> </div></div></p> </div> </div> </div> </footer> <div class="postFooter"> <div class="container"> <p>© 2000-2025 All rights reserved. American Society of Gene & Cell Therapy. </p> <p class="bkCredit"><a href="https://www.reasononeinc.com/kentico" title="BlueKey is a Full Service Digital Agency and Kentico Gold Partner. Click to learn more about our Kentico development services" target="_blank">Kentico CMS Development by Reason One</a> | <a href="http://www.kentico.com" target="_blank">Powered by Kentico</a></p> </div> </div> <script src="/BlueKey/assets/js/app-dist.js"></script> <script src="/BlueKey/assets/js/timeline-dist.js"></script> </div> <script type="text/javascript"> //<![CDATA[ if (typeof(Sys.Browser.WebKit) == 'undefined') { Sys.Browser.WebKit = {}; } if (navigator.userAgent.indexOf('WebKit/') > -1) { Sys.Browser.agent = Sys.Browser.WebKit; Sys.Browser.version = parseFloat(navigator.userAgent.match(/WebKit\/(\d+(\.\d+)?)/)[1]); Sys.Browser.name = 'WebKit'; } //]]> </script> <script type="text/javascript"> //<![CDATA[ var callBackFrameUrl='/WebResource.axd?d=nNME_ObE2oIDm535eYM9xWmIMy-HXBVdo54Ly6sA5tAYPS1aA-gFDzodlP9ijTBRgmjStONrH4-ISuRTp7slHiYkACw1&t=638628028040000000'; WebForm_InitCallback();//]]> </script> </form> </body> </html>